Zacks Investment Research upgraded shares of Eagle Pharmaceuticals (NASDAQ:EGRX) from a sell rating to a hold rating in a research report released on Tuesday.

According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “

Other equities analysts have also issued reports about the company. Mizuho upgraded Eagle Pharmaceuticals from an underperform rating to a neutral rating in a research note on Monday, June 11th. BidaskClub upgraded Eagle Pharmaceuticals from a hold rating to a buy rating in a research note on Saturday, September 29th. Royal Bank of Canada set a $84.00 price objective on Eagle Pharmaceuticals and gave the stock a buy rating in a research note on Wednesday, August 8th. Piper Jaffray Companies set a $88.00 price objective on Eagle Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, August 7th. Finally, Cantor Fitzgerald dropped their price objective on Eagle Pharmaceuticals from $81.00 to $80.00 and set a buy rating on the stock in a research note on Thursday, September 20th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $86.50.

Shares of Eagle Pharmaceuticals stock traded up $0.16 during trading on Tuesday, reaching $60.14. The company’s stock had a trading volume of 233,104 shares, compared to its average volume of 235,428. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.09 and a current ratio of 4.22. The firm has a market capitalization of $1.04 billion, a PE ratio of 17.85 and a beta of 1.32. Eagle Pharmaceuticals has a one year low of $48.84 and a one year high of $85.66.

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.80 by $0.15. The business had revenue of $59.30 million for the quarter, compared to analyst estimates of $51.78 million. Eagle Pharmaceuticals had a return on equity of 19.71% and a net margin of 13.81%. Research analysts forecast that Eagle Pharmaceuticals will post 2.15 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Metropolitan Life Insurance Co. NY increased its stake in Eagle Pharmaceuticals by 22.4% during the second quarter. Metropolitan Life Insurance Co. NY now owns 3,513 shares of the specialty pharmaceutical company’s stock valued at $266,000 after acquiring an additional 642 shares during the period. State of Alaska Department of Revenue increased its stake in Eagle Pharmaceuticals by 33.5% during the third quarter. State of Alaska Department of Revenue now owns 3,607 shares of the specialty pharmaceutical company’s stock valued at $250,000 after acquiring an additional 905 shares during the period. MetLife Investment Advisors LLC increased its stake in Eagle Pharmaceuticals by 22.5% during the second quarter. MetLife Investment Advisors LLC now owns 4,988 shares of the specialty pharmaceutical company’s stock valued at $377,000 after acquiring an additional 915 shares during the period. Macquarie Group Ltd. increased its stake in Eagle Pharmaceuticals by 400.0% during the second quarter. Macquarie Group Ltd. now owns 1,500 shares of the specialty pharmaceutical company’s stock valued at $113,000 after acquiring an additional 1,200 shares during the period. Finally, Meeder Asset Management Inc. increased its stake in Eagle Pharmaceuticals by 232.6% during the second quarter. Meeder Asset Management Inc. now owns 1,866 shares of the specialty pharmaceutical company’s stock valued at $141,000 after acquiring an additional 1,305 shares during the period.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Read More: How to interpret a stock’s beta number

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.